<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153334</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0277</org_study_id>
    <nct_id>NCT01153334</nct_id>
  </id_info>
  <brief_title>Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: An investigator-initiated, double-blind, randomized, placebo-controlled,
      multi-center study to evaluate the efficacy of early intensive rosuvastatin therapy
      (rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter)
      versus low dose conventional statin therapy (placebo for pre-PCI loading and rosuvastatin 10
      mg daily after primary PCI) on infarct size measured by cardiac MRI and clinical outcomes in
      STEMI patients undergoing primary percutaneous coronary intervention (PCI). Hypothesis: The
      infarct size in the early high dose rosuvastatin group is smaller than that of the control
      patients treated with low does conventional statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2010</start_date>
  <completion_date type="Actual">June 27, 2013</completion_date>
  <primary_completion_date type="Actual">June 27, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size measured by cardiac MRI</measure>
    <time_frame>day 3-7</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>ST-segment Elevation AMI</condition>
  <arm_group>
    <arm_group_label>Early intensive rosuvastatin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional statin therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)</intervention_name>
    <description>1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI</description>
    <arm_group_label>Early intensive rosuvastatin therapy</arm_group_label>
    <arm_group_label>Conventional statin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient had the symptoms of acute myocardial infarction within 12 hours with
             ST-segment elevation of more than 1 mm in at least two contiguous leads of EKG or new
             onset LBBB.

          2. Male or female over 20 years of age

          3. Signed written informed consent to participate in the study

        Exclusion Criteria:

          1. Congestive heart failure (NYHA Class III or IV) or LVEF &lt;35%.

          2. Clinically significant heart disease requiring CABG, cardiac transplantation, surgical
             repair and/or replacement during the course of the study.

          3. Previous MI or CABG

          4. Known serious or hypersensitivity reactions to statin, antiplatelet agents (aspirin or
             clopidogrel), or heparin.

          5. Known familial hypercholesterolemia

          6. Known skeletal muscle disease

          7. Known active liver disease such as hepatitis or liver cirrhosis (except for fatty
             liver)

          8. Renal failure (Cr &gt;2.0 mg/dL)

          9. Secondary causes of hyperlipoproteinemia: uncontrolled primary hypothyroidism, and/or
             nephrotic syndrome

         10. Non-cardiac comorbidity with a life expectation &lt; 1 year

         11. Contraindications to CMRI (eg, implanted pacemaker or cardiac defibrillator,
             claustrophobia, etc.)

         12. Pregnant or lactating women or women of childbearing potential

         13. Participation in any investigational drug or device study within 30 days prior to
             study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yangsoo Jang, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>November 26, 2017</last_update_submitted>
  <last_update_submitted_qc>November 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

